ST-001 trial for stubborn T-cell lymphoma that came back
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these confirmed T-cell lymphoma types: mycosis fungoides, Sézary syndrome, primary cutaneous CD30+ large cell lymphoma, or certain nodal T-cell lymphomas (PTCL NOS, AITL, or follicular T-cell lymphoma.
- Your lymphoma must be relapsed or refractory, meaning it returned after treatment or did not respond to the most recent treatment.
- You need at least one measurable active disease site for the study to track response.
- You must be at least 18 years old, able to do study procedures, and expected to live more than 6 months.
- Your recent treatments must be finished for long enough (usually at least 4 weeks; longer for some chemo types), and you must be recovered from side effects.
- Your organs and blood counts must be in acceptable ranges (blood counts, liver tests, kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DT-7012 for people with a type of skin lymphoma (mycosis fungoides or Sezary syndrome) that has come back or not responded to at least two prior treatments. The goal is to find a safe dose and see if it shrinks the lymphoma.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This trial tests a combination therapy with tazemetostat for people whose peripheral T-cell lymphoma has come back or hasn't responded to previous treatment. The goal is to see if this drug combination can help shrink tumors or slow the disease.
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
This trial tests a new drug, ST-067, combined with a CAR T-cell therapy (liso-cel) for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if the combination is safe and effective.
This trial tests a combination of belinostat (a targeted drug) plus either azacitidine or pralatrexate for people with relapsed or refractory T-cell lymphoma. The goal is to find a new treatment option when previous therapies have stopped working.
Hear when a new T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.